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RESEARCH NOTE
Voluntary exercise in mesothelioma: effects 
on tumour growth and treatment response 
in a murine model
Scott A. Fisher1,2*† , Carolyn J. Peddle‑McIntyre3,4†, Kimberley Burton1,2, Robert U.  Newton3,4,5, Elly Marcq6, 
Richard A. Lake1 and Anna K. Nowak1,7
Abstract 
Objective: There is substantial evidence that exercise can safely reduce the risk of cancer and improve survival in 
different human cancer populations. Long latency periods associated with carcinogen–induced cancers like asbestos 
induced mesothelioma provide an opportunity to implement exercise as an intervention to delay or prevent disease 
development. However, there are limited studies investigating the ability of exercise to prevent or delay cancer, and 
exercise as a preventive strategy has never been assessed in models with a known carcinogen. We investigated the 
potential of voluntary exercise (VE) to delay development of asbestos related disease (ARD) in our well‑characterised, 
asbestos induced MexTAg model of mesothelioma.
Results: Asbestos exposed MexTAg mice were given continuous or delayed access to VE and ARD assessed over 
time. We found that the addition of VE did not affect ARD development in asbestos exposed MexTAg mice. However, 
non–asbestos exposed, aged matched control mice participated in significantly more VE behaviours, suggesting sub‑
clinical development of ARD after asbestos exposure had a greater impact on VE participation than age alone. These 
data highlight the importance of model choice and the potential limitation that some pre–clinical studies may not 
accurately represent the clinical paradigm, particularly in the context of prevention studies.
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Introduction
Mesothelioma is an asbestos induced cancer with poor 
prognosis. Treatment is usually palliative, with systemic 
therapy providing limited survival benefit [1, 2]. Despite 
mesothelioma having a long latent period (20-40  years) 
between asbestos exposure and diagnosis [3], there are 
currently no effective strategies to prevent mesothelioma 
onset after asbestos exposure. Carcinogen induced can-
cers progress through multiple genetic, epigenetic and 
immunological modification, culminating in clinically 
apparent disease [4]. It is logical to hypothesise that some 
intervention during disease latency might delay onset of, 
or even prevent mesothelioma development. Such stud-
ies in humans require large participant numbers and take 
many years. However, animal studies allow for pre-clini-
cal testing of these hypotheses, and subsequent selection 
of effective treatments for clinical trials.
Strong epidemiological evidence indicates that physi-
cal activity is associated with a reduced risk of develop-
ing cancer [5]. Compared with being inactive, the highest 
levels of physical activity have been associated with a 25% 
reduction in incidence of breast and colorectal cancer [6, 
7]. Collectively, epidemiological evidence suggests that 
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many cancers. Exercise holds potential as an intervention 
to delay or prevent mesothelioma in asbestos exposed 
individuals. However, the ability of exercise to prevent or 
delay cancer has never been investigated in models with a 
known carcinogen.
Pre-clinical evidence demonstrates that voluntary exer-
cise (VE) can suppress tumour initiation and growth 
in mouse models of breast, colorectal and lung cancer 
[8–13]. Exercise induced suppression of tumour initia-
tion and growth may be mediated by effects on tumour 
metabolism and immune function. Inflammation is criti-
cal in cancer development and VE has been shown to 
attenuate the inflammatory response in mice following 
carcinogen exposure, promoting more efficient clearance 
of damaged cells [14]. Additionally, VE decreases tumour 
incidence and growth via regulation of key immune cells, 
including natural killer (NK) and effector lymphocytes 
[13]. Here we investigated the potential of VE to delay 
development of asbestos related disease (ARD) in our 
well–characterised, asbestos induced MexTAg mouse 




Experiments were approved by the UWA AEC 
(RA/3/100/1514) in accordance with the Australian 
code for the use of animals in medical research [17]. The 
C57Bl/6 derived 266 MexTAg transgenic mouse model 
expressing the Simian Virus 40 (SV40) Large  T  antigen 
(TAg) under the control of the mesothelin promoter has 
been described [15, 16]. For all experiments MexTAg 
mice (28–30/group, M&F, 6–20  weeks) were randomly 
assigned to their experimental groups and housed 3 
per cage (Thoren cage; 19.56 × 30.91 × 13.34  cm) under 
standard conditions with food (standard meat free mouse 
and rat diet. Specialty feeds, Perth W.A. Cereal grain 
based diet, 12  mm pellets, digestible energy 14  MJ/kg) 
and water provided ad libitum. Mice were euthanised via 
methoxyflurane anaesthesia immediately prior to cervical 
dislocation. The extended duration of experiments and 
overt nature of ARD prevented blinding of investigators 
to treatment groups.
MexTAg mice and asbestos instillation
MexTAg mice were exposed to crocidolite asbestos via 
two, 0.5  ml (3  mg) intraperitoneal (i.p.) injections per 
mouse at weeks 0 and 4, monitored at least twice weekly 
and euthanised when ARD became evident; commonly 
ascites induced abdominal distension. ARD development 
and mesothelioma incidence was confirmed on histology 
as previously described [15, 16].
Voluntary exercise (VE)
VE was assessed by placing an activated or locked low 
profile wireless running wheel (Med Associates  Inc®, 
USA.) into each cage and data collected using the USB 
Interface Hub and computer running SOF 860 Wheel 
Manager software. Mice were acclimatised and trained 
on running wheels for 1 week prior to start of experi-
ment. Actogram analysis was performed using SOF 
861 Wheel Analysis software, while assessment of VE 
parameters such as time spent running and distance 
run was performed using Microsoft Excel. Data was 
collected 24/7.
Statistics
Comparisons between two individual, or three or 
more groups were performed using unpaired, non-
parametric (Mann–Whitney) Student’s t test (with 
Holm-Sidak correction for multiple comparisons), or 
unpaired, ordinary one-way ANOVA with Dunnett’s 
correction for multiple comparison respectively, rela-
tive to first data point. Log rank (Mantel-Cox) analysis 
was performed on survival curves. Analyses were per-
formed using Graph Pad Prism Software V8 (Graph 
Pad Software Inc., USA). We used R [18] with afex [19] 
and emmeans [20] packages to perform mixed model 
ANOVA to analyse differences in VE behaviour over 
time. p values ≤ 0.05 were considered significant.
Results
Nocturnal peak in voluntary exercise
To assess the impact of voluntary exercise on ARD, 
asbestos exposed MexTAg mice (28–30/group) were 
randomly assigned to No VE or VE groups that either 
had continuous access to activated running wheels 
(Pre-exposure group (Pre–VE); starting 2 weeks before 
asbestos instillation), or from 25  weeks after asbestos 
instillation (Post exposure group (Post–VE), Fig.  1a). 
Age matched, non–asbestos exposed MexTAg mice 
served as controls to assess changes in exercise behav-
iour over time in the absence of asbestos (Fig. 1b). All 
mice were assessed for overall survival, while asbestos 
exposed mice were additionally assessed for disease 
latency; time from asbestos exposure to first signs of 
disease (FSD) and disease progression; time from FSD 
until cull.
Although voluntary exercise activity was collected con-
tinuously throughout the experiment, we first sought to 
identify the circadian pattern of VE. We observed high 
levels of running wheel activity between 2200  h and 
0600 h, within any 24 h period for all VE groups (Fig. 1c). 
Based on these findings, all subsequent analysis of VE 
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parameters was performed on data obtained within this 
period.
Voluntary exercise does not affect asbestos related disease 
development in MexTAg mice
No difference in median survival was observed between 
asbestos exposed mice given access to VE compared 
to the No VE control group (Pre-VE vs. No VE; 39.9 
vs. 45.3  weeks, p = 0.2784; Post–VE vs. No VE; 44.9 vs. 
45.3  weeks p = 0.7404), with all but 3  mice (2 from No 
VE and 1 from Post VE) succumbing to ARD by 70 weeks 
(Fig.  2a). No difference was observed in disease latency 
between asbestos exposed groups relative to No VE con-
trols (Pre–VE 39.3 weeks (p = 0.72); Post–VE 42.9 weeks 
(p < 0.99 vs. No VE 43.1  weeks), or disease progres-
sion (Pre–VE 0.3  weeks (p < 0.99), Post–VE 0.1  weeks 
(p < 0.99) vs. No VE 0.3  weeks; Fig.  2b, c). In contrast, 
all age matched, non–asbestos exposed control mice 
survived to the 70 week experimental endpoint (Fig. 2a, 
dashed lines).
Asbestos exposure diminishes exercise participation
We next assessed the time spent running per night 
and total distance run per night to determine whether 
Fig. 1 Peak VE activity occurs between 2200 and 0600 h. a Schematic of experimental design. MexTAg mice (n = 28‑30/group, 3 mice per cage) 
were exposed to asbestos (6 mg total over 2 i.p. injections 4 week apart; black arrows) in the presence or absence of active running wheels (icons) 
as indicated. b Age distribution (median + range) between experimental and control groups. Age matched (Young: 90 days; Old (25 weeks) 
265 days), non‑asbestos exposed mice were used as controls to assess the impact of exercise over time in the absence of asbestos exposure. c 
Actogram depicting VE (active wheel running) over 6 consecutive days. Peak VE activity consistently occurred over an 8 h period between 2200 and 
0600 h. Data shown are from a single cage from the Pre‑Exp VE group and are representative of all VE groups. Data was collected 24/7 for 70 weeks 
and data between 2200 and 0600 h used for analysis
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VE participation changed over time. All asbestos 
exposed mice displayed a progressive decline in exer-
cise (time and distance run per night) over the 70-week 
experimental duration. For Pre–VE and Post–VE groups, a 
significant decline for both time spent running per 
night and total distance run per night, was observed 
Fig. 2 Voluntary exercise does not affect asbestos related disease in MexTAg mice. Crocidolite asbestos (6 mg total) was injected into MexTAg mice 
via two intraperitoneal injections four weeks apart. a Kaplan–Meier plot depicting survival over a 70 week period with the number of mice at risk 
shown in the corresponding table. b ARD Latency (time from asbestos exposure to first signs of disease) and c progression (time from first signs of 
disease until cull) in asbestos‑exposed groups. Table define experimental design and cohort characteristics. Data are censored for asbestos related 
deaths and show mean ± SD. Log–rank (Mantel‑Cox) analysis was used for survival. Kruskal–Wallis one‑way ANOVA with Dunn’s test for multiple 
comparisons for all other analyses. p values ≤ 0.05 were considered significant. A single age‑matched, non‑asbestos exposed mouse was culled at 
week 44 in an incident unrelated to VE
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after 15  weeks of access to VE (Pre–VE running time/
night: starting 16–20  weeks, p = 0.018 and distance/
night: p = 0.028, sustained from 21 to 65  weeks, 
p < 0.0001; Post–VE time/night: starting 41–45  weeks 
(p = 0.002) and distance/night (p = 0.015), sustained from 
46–70 weeks, both p < 0.0001; Fig. 3a–d). Whilst VE par-
ticipation at 26–30  weeks was similar between Pre–VE 
and Post–VE groups, the Post–VE group showed a more 
profound and sustained reduction in exercise behaviours 
over time, with VE participation being almost negligible 
for mice surviving to 70 weeks (Fig. 3a, b vs. c, d).
To determine whether the decline in VE in asbestos 
exposed mice was affected by how old mice were when 
given access to VE, we repeated the experiment using 
non–asbestos exposed mice. Two groups, ‘Young’ or ‘Old’, 
were used as aged matched controls for Pre-VE (Young; 
90  days at start of VE) and Post–VE (Old; 265  days at 
start of VE) groups respectively. Although a significant 
decrease in VE participation was observed within both 
control groups over time (p < 0.01), this decrease was 
not as marked in comparison to their respective asbes-
tos-exposed groups (1.51 to 4.28-fold decrease vs 2.97 
to 12.63 fold decrease non–asbestos vs asbestos exposed 
groups respectively). Magnitude of decrease in distance 
run per night was most pronounced in the Post–VE 
group (Fig. 3e–h).
This was further evident when we compared changes 
in VE over time between asbestos exposed VE groups 
and their respective control group, where both groups 
of asbestos exposed mice consistently spent significantly 
less time running, and ultimately travelled less distance 
per night, relative to their respective non–asbestos 
exposed control (Fig.  3i–n). Interestingly, VE participa-
tion in age matched, non-asbestos exposed controls in 
which VE was delayed (Old controls) was significantly 
higher (p < 0.05) relative to the continuous VE (Young) 
control group (Fig.  3m–n), suggesting that older mice 
might be more responsive to VE intervention. Taken 
together, these data indicate that asbestos exposed mice 
had reduced VE participation over time suggesting that 
the subclinical development of ARD after asbestos expo-
sure had a greater impact on VE participation than age 
alone.
Discussion
Here we employed our asbestos induced MexTAg 
mouse model to assess the impact of VE on ARD fol-
lowing asbestos exposure. In contrast to other studies in 
which VE delayed tumour growth [13], the addition of 
VE (continuous or delayed) did not affect ARD develop-
ment in our model. Mesothelioma is unusual in that the 
carcinogen, asbestos, induces a similar disease in mice 
and humans. This is rare in cancer research and pre-
sents an ideal opportunity to apply small animal mod-
els to advance mesothelioma prevention and treatment. 
However, model choice may explain why VE did not 
have any significant impact on ARD in asbestos exposed 
MexTAg mice. Previous studies demonstrating signifi-
cant VE associated reduction in tumour incidence and 
growth employed mouse models employing intrave-
nously or subcutaneous tumours [8–13]. In these stud-
ies, VE enhanced tumour suppression was associated 
with increased expression of p53 and mediators of apop-
tosis [9], or mobilisation and redistribution of NK cells 
in an epinephrine and IL–6 dependent manner [13]. In 
contrast, the MexTAg model involves induction of ARD 
in  situ following asbestos exposure, where TAg expres-
sion phenocopies p16 loss, effectively bypassing p53/p16 
mediated cell cycle control [21]. Therefore, the inherent 
genetic modifications that drive the oncogenic potential 
in transgenic models like MexTAg might mask any ben-
efit induced by supportive adjuvant therapies like VE.
While we did not observe differences in ARD, we 
did observe significant differences in VE participa-
tion between, and within asbestos exposed and non–
exposed groups. In particular, VE participation was 
higher in age matched, non-asbestos controls in which 
VE was delayed (Old) relative to asbestos exposed 
delayed VE and the continuous (Young) VE control 
group; indicating that asbestos exposure, rather than 
age, had a greater impact on the observed reduc-
tion in VE participation over time. We also observed 
a decrease in exercise prior to clinical signs of disease 
development in asbestos exposed mice. It is important 
to consider these data in context of the clinical set-
ting, in which mesothelioma patients are often elderly, 
have a sedentary lifestyle and present with high disease 
Fig. 3 Diminished capacity for VE after asbestos‑exposure. MexTAg mice given access to VE either 2‑weeks before (Pre‑Exp VE), or 25‑weeks after 
(Post‑Exp VE) asbestos exposure displayed a significant and sustained decrease in both the amount of time spent running/night (a, c) and total 
distance travelled/night (b, d) over a 70 week period. This was in contrast to age‑matched, non‑asbestos exposed MexTAg controls (e–h), which 
maintained significantly higher VE capacity over a similar time period. (i-n) Changes in VE over time between respective asbestos exposed and 
age‑matched, non‑asbestos exposed control groups (i, j: Pre‑Exp VE vs Young Ctrl; k, l: Post‑Exp VE vs Old Ctrl and m, n Young vs. Old controls). 
Table depicts fold‑change over time. Data shown is mean ± SD. (a–h) Data analysed using a non‑parametric Kruskal–Wallis one way ANOVA 
with Dunn’s test for multiple comparisons to start of VE. (i–n) Data analysed via non‑parametric, mixed model ANOVA. * = p<0.05, ** = p<0.01, 
*** = p<0.001, **** = p<0.0001
(See figure on next page.)
Page 6 of 8Fisher et al. BMC Res Notes          (2020) 13:435 
Page 7 of 8Fisher et al. BMC Res Notes          (2020) 13:435  
burden [22, 23]. Together, these data suggest that the 
impact of VE on asbestos induced ARD might be better 
observed and modelled using aged mice. Alternatively, 
our recent human data [24] demonstrated that a short 
(six–week) tailored resistance exercise training pro-
gram was well tolerated and beneficial to mesothelioma 
patients. As data in this study also indicated a decrease 
in exercise preceded disease detection, this may sug-
gest that patients presenting with mesothelioma might 
benefit from additional support and rehabilitation at 
diagnosis.
In conclusion, the addition of continuous or delayed 
VE did not significantly affect ARD development in 
asbestos exposed MexTAg mice. Our data is in con-
trast to previous studies and highlights the impor-
tance of choosing an appropriate model and rigorously 
evaluating model parameters. Preclinical transplant 
models might be useful for ‘proof of concept’ stud-
ies, but as seen here, may not be applicable across dif-
ferent tumour types and may not phenocopy in  situ 
development of human cancer. Additionally, our study 
highlights that exercise alone may not be sufficient to 
counteract the oncogenic potential of strong carcino-
gens like asbestos. As such, some pre–clinical studies 
may not accurately represent the clinical paradigm, 
particularly in the context of prevention style studies, 
and therefore have limited translational impact.
Limitations
Study-specific limitations include: 3 mice per cage–
therefore, exercise data is not indicative of an individual 
mouse; Furthermore, similar ARD development across 
all groups might simply suggest that other modes of indi-
vidualized exercise, rather than continuous VE used in 
this and other studies [8–13], might be more effective as 
adjunct supportive treatment for mesothelioma.
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